Literature DB >> 20622401

Posaconazole.

M Bhattacharya1, K Rajeshwari, B Dhingra.   

Abstract

Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622401     DOI: 10.4103/0022-3859.65281

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  1 in total

1.  Posaconazole treatment in Korea: single-center experience over 5 years.

Authors:  Hyo-Jin Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi; Dong-Gun Lee; Sun-Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Byung-Sik Cho; Seok Lee; Hee-Je Kim; Chang-Ki Min; Jong-Wook Lee; Woo-Sung Min
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.